Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate AVX/COVID-12 Activates T Cells and Is Recognized by Antibodies from COVID-19 Patients and Vaccinated
Alejandro Torres-Flores, Luis Alberto Ontiveros-Padilla, Ruth Lizzeth Madera-Sandoval…·Constantino III Roberto López-Macías
This paper evaluates the AVX/COVID-12 vaccine's ability to activate T cells and bind antibodies from vaccinated individuals and SARS-CoV-2-infected patients.